Tetrahydrouridine + Decitabine
Phase 1 Study of Oral Tetrahydrouridine-Decitabine to Treat Relapsed or Refractory Myelodysplastic Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 20 patients (estimated)
- Sponsors
- EpiDestiny, Inc.
- Tags
- Cytidine Deaminase Inhibitor (CDAi)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2129
- NCT Identifier
- NCT07006025
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.